CNSP
CNS Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.11
−0.20%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.12
From 52W high−51.66%
Volume4384.00
Market cap$7.47M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$5.12
From 52W high
−51.66%
Volume
4384.00
Market cap
$7.47M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.8x
P/E (TTM)
—
RSI (14)
38.8
MomentumView details →
1D Return
−0.20%
YTD Return
−3.24%
SummaryUpdated Jun 1, 2026
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Houston, Texas. The company went public in November 2019 and focuses exclusively on developing novel anti-cancer drug candidates for treating brain and central nervous system tumors, one of the most challenging areas in oncology. CNS Pharmaceuticals operates as a development-stage company with no commercial products yet approved for sale.
Similar companies
Latest newsMore news →
No recent news for CNSP.